Drug maker Bristol-Myers Squibb foresees significant effects on its business from the Patient Protection and Affordable Care Act, company executives told attendees of its recent shareholder meeting.
Bristol-Myers Squibb announced changes to its senior management team, including the appointment of its U.S. pharmaceuticals president.
